tbuckley/cabot-search huggingface dataset:
The combination of tumor mutational burden and T‐cell receptor repertoire predicts the response to immunotherapy in patients with advanced non–small cell lung cancer
Authors: Yalun Li, Liyan Ji, Yingqian Zhang, Jiexin Zhang, Alexandre Reuben, Hao Zeng, Qin Huang, Qi Wei, Sihan Tan, Xuefeng Xia, Weimin Li, Jianjun Zhang, Panwen Tian
Journal: MedComm (2024)

Abstract Tumor mutational burden (TMB) and T‐cell receptor (TCR) might predict the response to immunotherapy in patients with non–small cell lung cancer (NSCLC). However, the predictive value of the combination of TMB and TCR was not clear. Targeted DNA and TCR sequencing were performed on tumor biopsy specimens. We combined TMB and TCR diversity into a TMB‐and‐TCR (TMR) score using logistic regression. In total, 38 patients with advanced NSCLC were divided into a discovery set ( n = 17) and validation set ( n = 21). A higher TMR score was associated with better response and longer progression‐free survival to immunotherapy in both the discovery set and validation set. The performance of TMR score was confirmed in the two external validation cohorts of 225 NSCLC patients and 306 NSCLC patients. Tumors with higher TMR scores were more likely to combine with LRP1B gene mutation ( p = 0.027) and top 1% CDR3 sequences ( p = 0.001). Furthermore, LRP1B allele frequency was negatively correlated with the top 1% CDR3 sequences ( r = –0.55, p = 0.033) and positively correlated with tumor shrinkage ( r = 0.68, p = 0.007). The TMR score could serve as a potential predictive biomarker for the response to immunotherapy in advanced NSCLC.
Thromboembolic events and vascular dementia in patients with atrial fibrillation and low apparent stroke risk
Authors: Alastair R. Mobley, Anuradhaa Subramanian, Asgher Champsi, Xiaoxia Wang, Puja Myles, Paul McGreavy, Karina V. Bunting, David Shukla, Krishnarajah Nirantharakumar, Dipak Kotecha
Journal: Nature Medicine (2024)

The prevention of thromboembolism in atrial fibrillation (AF) is typically restricted to patients with specific risk factors and ignores outcomes such as vascular dementia. This population-based cohort study used electronic healthcare records from 5,199,994 primary care patients (UK; 2005-2020). A total of 290,525 (5.6%) had a diagnosis of AF and were aged 40-75 years, of which 36,340 had no history of stroke, a low perceived risk of stroke based on clinical risk factors and no oral anticoagulant prescription. Matching was performed for age, sex and region to 117,298 controls without AF. During 5 years median follow-up (831,005 person-years), incident stroke occurred in 3.8% with AF versus 1.5% control (adjusted hazard ratio (HR) 2.06, 95% confidence interval (CI) 1.91-2.21; P < 0.001), arterial thromboembolism 0.3% versus 0.1% (HR 2.39, 95% CI 1.83-3.11; P < 0.001), and all-cause mortality 8.9% versus 5.0% (HR 1.44, 95% CI 1.38-1.50; P < 0.001). AF was associated with all-cause dementia (HR 1.17, 95% CI 1.04-1.32; P = 0.010), driven by vascular dementia (HR 1.68, 95% CI 1.33-2.12; P < 0.001) rather than Alzheimer's disease (HR 0.85, 95% CI 0.70-1.03; P = 0.09). Death and thromboembolic outcomes, including vascular dementia, are substantially increased in patients with AF despite a lack of conventional stroke risk factors.
Chemoproteomics enables identification of coatomer subunit zeta‐1 targeted by a small molecule for enterovirus A71 inhibition
Authors: Xiaoyong Li, Jin Zhang, Yaxin Xiao, Hao Song, Yuexiang Li, Wei Li, Ruiyuan Cao, Song Li, Yong Qin, Chu Wang, Wu Zhong
Journal: MedComm (2024)

Abstract Human enterovirus A71 (EV‐A71) is a significant etiological agent responsible for epidemics of hand, foot, and mouth disease (HFMD) in Asia‐Pacific regions. There are presently no licensed antivirals against EV‐A71, and the druggable target for EV‐A71 remains very limited. The phenotypic hit 10,10′‐bis(trifluoromethyl) marinopyrrole A derivative, herein termed MPA‐CF 3 , is a novel potent small‐molecule inhibitor against EV‐A71, but its pharmacological target(s) and antiviral mechanisms are not defined. Here, quantitative chemoproteomics deciphered the antiviral target of MAP‐CF 3 as host factor coatomer subunit zeta‐1 (COPZ1). Mechanistically, MPA‐CF 3 disrupts the interaction of COPZ1 with the EV‐A71 nonstructural protein 2C by destabilizing COPZ1 upon binding. The destruction of this interaction blocks the coatomer‐mediated transport of 2C to endoplasmic reticulum, and ultimately inhibits EV‐A71 replication. Taken together, our study disclosed that MPA‐CF 3 can be a structurally novel host‐targeting anti‐EV‐A71 agent, providing a structural basis for developing the COPZ1‐targeting broad‐spectrum antivirals against enteroviruses. The mechanistic elucidation of MPA‐CF 3 against EV‐A71 may offer an alternative COPZ1‐involved therapeutic pathway for enterovirus infection.
Cell-type-specific effects of age and sex on human cortical neurons
Authors: Jo-Fan Chien, Hanqing Liu, Bang-An Wang, Chongyuan Luo, Anna Bartlett, Rosa Castanon, Nicholas D. Johnson, Joseph R. Nery, Julia Osteen, Junhao Li, Jordan Altshul, Mia Kenworthy, Cynthia Valadon, Michelle Liem, Naomi Claffey, Carolyn O'Connor, Luise A. Seeker, Joseph R. Ecker, M. Margarita Behrens, Eran A. Mukamel
Journal: Neuron (2024)

Altered transcriptional and epigenetic regulation of brain cell types may contribute to cognitive changes with advanced age. Using single-nucleus multi-omic DNA methylation and transcriptome sequencing (snmCT-seq) in frontal cortex from young adult and aged donors, we found widespread age- and sex-related variation in specific neuron types. The proportion of inhibitory SST- and VIP-expressing neurons was reduced in aged donors. Excitatory neurons had more profound age-related changes in their gene expression and DNA methylation than inhibitory cells. Hundreds of genes involved in synaptic activity, including EGR1, were less expressed in aged adults. Genes located in subtelomeric regions increased their expression with age and correlated with reduced telomere length. We further mapped cell-type-specific sex differences in gene expression and X-inactivation escape genes. Multi-omic single-nucleus epigenomes and transcriptomes provide new insight into the effects of age and sex on human neurons.
A single-cell transcriptome atlas of human euploid and aneuploid blastocysts
Authors: Shengpeng Wang, Lizhi Leng, Quanlei Wang, Yifan Gu, Jinlu Li, Yanru An, Qiuting Deng, Pingyuan Xie, Can Cheng, Xueqin Chen, Qinwei Zhou, Jia Lu, Fang Chen, Longqi Liu, Huanming Yang, Jian Wang, Xun Xu, Yong Hou, Fei Gong, Liang Hu, Guangxiu Lu, Zhouchun Shang, Ge Lin
Journal: Nature Genetics (2024)
CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial
Authors: E. William St. Clair, Alan N. Baer, Wan-Fai Ng, Ghaith Noaiseh, Chiara Baldini, Teresa K. Tarrant, Athena Papas, Valerie Devauchelle-Pensec, Liangwei Wang, Wenjing Xu, Tuyet-Hang Pham, Keith Sikora, William A. Rees, Ilias Alevizos
Journal: Nature Medicine (2024)

Abstract Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease with no approved disease-modifying therapies. Dazodalibep (DAZ), a novel nonantibody fusion protein, is a CD40 ligand antagonist that blocks costimulatory signals between T and B cells and antigen-presenting cells, and therefore may suppress the wide spectrum of cellular and humoral responses that drive autoimmunity in SjD. This study was a phase 2, randomized, double-blinded, placebo (PBO)-controlled trial of DAZ with a crossover stage in two distinct populations of participants with SjD. Population 1 had moderate-to-severe systemic disease activity and population 2 had an unacceptable symptom burden and limited systemic organ involvement. All participants had a diagnosis of SjD, with 21.6% and 10.1% having an associated connective tissue disease (rheumatoid arthritis or systemic lupus erythematosus) in populations 1 and 2, respectively. The remaining participants would be considered as having primary Sjögren’s syndrome. The primary endpoint for population 1 ( n = 74) was the change from baseline in the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index at day 169. The primary endpoint for population 2 ( n = 109) was the change from baseline in the European League Against Rheumatism Sjögren’s Syndrome Patient Reported Index at day 169. The primary endpoints (least squares mean ± standard error) were achieved with statistical significance for both population 1 (DAZ, −6.3 ± 0.6; PBO, −4.1 ± 0.6; P = 0.0167) and population 2 (DAZ, −1.8 ± 0.2; PBO, −0.5 ± 0.2; P = 0.0002). DAZ was generally safe and well tolerated. Among the most frequently reported adverse events were COVID-19, diarrhea, headache, nasopharyngitis, upper respiratory tract infection, arthralgia, constipation and urinary tract infection. In summary, DAZ appears to be a potential new therapy for SjD and its efficacy implies an important role for the CD40/CD40 ligand pathway in its pathogenesis. ClinicalTrials.gov identifier: NCT04129164 .
A novel circPIK3C2A/miR‐31‐5p/TFRC axis drives ferroptosis and accelerates myocardial injury
Authors: Shuo Miao, Lanting Yang, Tao Xu, Zhantao Liu, Yixiao Zhang, Lin Ding, Wei Ding, Xiang Ao, Jianxun Wang
Journal: MedComm (2024)

Iron overload is common in cardiovascular disease, it is also the factor that drives ferroptosis. Noncoding RNAs play an important role in heart disease; however, their regulatory role in iron overload-mediated ferroptosis remains much unknown. In our study, the iron overload model in mice was constructed through a high-iron diet, and ammonium iron citrate treatment was used to mimic iron overload in vitro. We found iron overload induced ferroptosis in cardiomyocytes, which was dependent on the high expression of transferrin receptor (TFRC). MiR-31-5p was downregulated during iron overload; it inhibited cardiomyocyte ferroptosis by targeting TFRC. CircPIK3C2A, a highly expressed circRNA in the heart, was upregulated when iron was overloaded. CircPIK3C2A enhanced the expression of TFRC by sponging miR-31-5p and promoted ferroptosis during iron overload. Our results reveal a novel mechanistic insight into noncoding RNA-based ferroptosis and identify the circPIK3C2A/miR-31-5p/TFRC axis as a promising therapeutic target for myocardial damage.
CRISPR-Cas9 gene editing strengthens cuproptosis/chemodynamic/ferroptosis synergistic cancer therapy
Authors: Xiaoyu Wu, Zijun Bai, Hui Wang, Hanqing Wang, Dahai Hou, Yunzhu Xu, Guanqun Wo, Haibo Cheng, Dongdong Sun, Weiwei Tao
Journal: Acta Pharmaceutica Sinica B (2024)

Copper-based nanomaterials demonstrate promising potential in cancer therapy. Cu
The browning and mobilization of subcutaneous white adipose tissue supports efficient skin repair
Authors: Junrong Cai, Yuping Quan, Shaowei Zhu, None Jiayan Lin, Qian Zhang, Juzi Liu, Zhuokai Liang, Yunjun Liao, Wenqing Jiang, Yufei He, Ting Su, Feng Lu
Journal: Cell Metabolism (2024)
Ultrasensitive Monolithic Dopamine Microsensors Employing Vertically Aligned Carbon Nanofibers
Authors: Lingju Meng, Maedeh Akhoundian, Anas Al Azawi, Yalda Shoja, Pei‐Yin Chi, Kristoffer Meinander, Sami Suihkonen, Sami Franssila
Journal: Advanced Healthcare Materials (2024)

Brain-on-Chip devices, which facilitate on-chip cultures of neurons to simulate brain functions, are receiving tremendous attention from both fundamental and clinical research. Consequently, microsensors are being developed to accomplish real-time monitoring of neurotransmitters, which are the benchmarks for neuron network operation. Among these, electrochemical sensors have emerged as promising candidates for detecting a critical neurotransmitter, dopamine. However, current state-of-the-art electrochemical dopamine sensors are suffering from issues like limited sensitivity and cumbersome fabrication. Here, a novel route in monolithically microfabricating vertically aligned carbon nanofiber electrochemical dopamine microsensors is reported with an anti-blistering slow cooling process. Thanks to the microfabrication process, microsensors is created with complete insulation and large surface areas. The champion device shows extremely high sensitivity of 4.52× 10
Cardiovascular Magnetic Resonance Before Invasive Coronary Angiography in Suspected Non–ST-Segment Elevation Myocardial Infarction
Authors: Mayooran Shanmuganathan, Chrysovalantou Nikolaidou, Matthew K. Burrage, Alessandra Borlotti, Rafail Kotronias, Roberto Scarsini, Abhirup Banerjee, Dimitrios Terentes-Printzios, Alex Pitcher, Edit Gara, Jeremy Langrish, Andrew Lucking, Robin Choudhury, Giovanni Luigi De Maria, Adrian Banning, Stefan K. Piechnik, Keith M. Channon, Vanessa M. Ferreira
Journal: JACC. Cardiovascular imaging (2024)

In suspected non-ST-segment-elevation myocardial infarction (NSTEMI), this presumed diagnosis may not hold true in all cases, particularly in patients with non-obstructive coronary arteries (NOCA). Additionally, in multi-vessel coronary artery disease (MVD), the presumed infarct-related artery (IRA) may be incorrect. To assess the diagnostic utility of cardiovascular magnetic resonance (CMR) before invasive coronary angiogram (ICA) in suspected NSTEMI. 100 consecutive stable patients with suspected acute NSTEMI (70% male, age 62±11 years) prospectively underwent CMR pre-ICA to assess cardiac function (cine), edema (T2-weighted imaging, T1-mapping) and necrosis/scar (late gadolinium enhancement). CMR images were interpreted blinded to ICA findings. The clinical care and ICA teams were blinded to CMR findings until post-ICA. Early CMR (median 33 hours post-admission and 4 hours pre-ICA) confirmed only 52% (52/100) subendocardial infarction, 15% transmural infarction, 18% non-ischemic pathologies (myocarditis, Takotsubo, cardiomyopathies) and 11% normal CMR. 4% were non-diagnostic. Sub-analyses according to ICA findings showed that, in patients with obstructive CAD (73/100), CMR confirmed only 84% (61/73) MI, 10% (7/73) non-ischemic pathologies and 5% (4/73) normal. In patients with NOCA (27/100), CMR found MI in only 22% (6/27 true MINOCA) and reclassified the presumed diagnosis of NSTEMI in 67% (18/27: 11 non-ischemic pathologies, 7 normal). In patients with CMR-MI and obstructive CAD (61/100), CMR identified a different IRA in 11% (7/61). In patients presenting with suspected NSTEMI, a CMR-first strategy identified MI in 67%, non-ischaemic pathologies in 18% and normal findings in 11%. has Accordingly, CMR has the potential to impact at least 50% of all patients by reclassifying their diagnosis or altering their potential management.
Dysfunctional circadian clock accelerates cancer metastasis by intestinal microbiota triggering accumulation of myeloid-derived suppressor cells
Authors: Jing-Lin Liu, Xu Xu, Youlutuziayi Rixiati, Chu-Yi Wang, Heng-Li Ni, Wen-Shu Chen, Hui-Min Gong, Zi-Long Zhang, Shi Li, Tong Shen, Jian-Ming Li
Journal: Cell Metabolism (2024)
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study
Authors: Joachim G Aerts, Robert Belderbos, Paul Baas, Arnaud Scherpereel, Koen Bezemer, Ilona Enninga, Rob Meijer, Marcella Willemsen, Rossana Berardi, Dean Fennell, Rene Kerstens, Robin Cornelissen, Jan P van Meerbeeck
Journal: The Lancet Oncology (2024)
Helpless infants are learning a foundation model
Authors: Rhodri Cusack, Marc’Aurelio Ranzato, Christine J. Charvet
Journal: Trends in Cognitive Sciences (2024)

Humans have a protracted postnatal helplessness period, typically attributed to human-specific maternal constraints causing an early birth when the brain is highly immature. By aligning neurodevelopmental events across species, however, it has been found that humans are not born with especially immature brains compared with animal species with a shorter helpless period. Consistent with this, the rapidly growing field of infant neuroimaging has found that brain connectivity and functional activation at birth share many similarities with the mature brain. Inspired by machine learning, where deep neural networks also benefit from a 'helpless period' of pre-training, we propose that human infants are learning a foundation model: a set of fundamental representations that underpin later cognition with high performance and rapid generalisation.
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule
Authors: Moufida Ben Nasr, Vera Usuelli, Sergio Dellepiane, Andy Joe Seelam, Teresa Vanessa Fiorentino, Francesca D’Addio, Emma Fiorina, Cong Xu, Yanan Xie, Hari Baskar Balasubramanian, Eduardo Castillo-Leon, Lara Loreggian, Anna Maestroni, Emma Assi, Cristian Loretelli, Ahmed Abdelsalam, Basset El Essawy, Silvia Uccella, Ida Pastore, Maria Elena Lunati, Gianmarco Sabiu, Adriana Petrazzuolo, Giacomo Ducci, Elena Sacco, Lucia Centofanti, Massimo Venturini, Serena Mazzucchelli, Deborah Mattinzoli, Masami Ikehata, Giuseppe Castellano, Gary Visner, Liu Kaifeng, Kang Mi Lee, Zhimin Wang, Domenico Corradi, Stefano La Rosa, Silvio Danese, Jun Yang, James F. Markmann, Gian Vincenzo Zuccotti, Reza Abdi, Franco Folli, Paolo Fiorina
Journal: Cell Metabolism (2024)
Child health prioritisation in national adaptation policies on climate change: a policy document analysis across 160 countries
Authors: Kathrin E Zangerl, Katarina Hoernke, Marike Andreas, Sarah L Dalglish, Ilan Kelman, Maria Nilsson, Joacim Rockloev, Till Bärnighausen, Shannon A McMahon
Journal: The Lancet Child & Adolescent Health (2024)
Coxsackievirus A10 impairs nail regeneration and induces onychomadesis by mimicking DKK1 to attenuate Wnt signaling
Authors: Yingzi Cui, Qiaoni Shi, Pu Song, Jianyu Tong, Zhimin Cheng, Hangchuan Zhang, Xiaodan Wang, Yuxuan Zheng, Yao Wu, Meng Wan, Shihua Li, Xin Zhao, Zhou Tong, Zhengquan Yu, Shan Gao, Ye-Guang Chen, George Fu Gao
Journal: The Journal of Experimental Medicine (2024)

Coxsackievirus A10 (CV-A10) infection, a prominent cause of childhood hand-foot-and-mouth disease (HFMD), frequently manifests with the intriguing phenomenon of onychomadesis, characterized by nail shedding. However, the underlying mechanism is elusive. Here, we found that CV-A10 infection in mice could suppress Wnt/β-catenin signaling by restraining LDL receptor–related protein 6 (LRP6) phosphorylation and β-catenin accumulation and lead to onychomadesis. Mechanistically, CV-A10 mimics Dickkopf-related protein 1 (DKK1) to interact with Kringle-containing transmembrane protein 1 (KRM1), the CV-A10 cellular receptor. We further found that Wnt agonist (GSK3β inhibitor) CHIR99021 can restore nail stem cell differentiation and protect against nail shedding. These findings provide novel insights into the pathogenesis of CV-A10 and related viruses in onychomadesis and guide prognosis assessment and clinical treatment of the disease.
Letter to the Editor: New confounders emerging with new evidence regarding reduced HCC and improved survival
Authors: Yue Hu, Zheng Li, Qiang Li, Xiaodong Jin, Cuixia Di, Weilan He, Xinran Cheng
Journal: Hepatology (2024)

Hu, Yue; Li, Zheng; Li, Qiang; Jin, Xiaodong; Di, Cuixia; He, Weilan; Cheng, Xinran Author Information
Reply: New confounders emerging with new evidence regarding reduced HCC and improved survival
Authors: Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
Journal: Hepatology (2024)

1College of Medicine, Chang Gung University, Taipei, Taiwan 2Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan 3Liver Research Unit, Chang Gung Memorial Hospital, Taiwan Correspondence Yun-Fan Liaw, Liver Research Unit, Chang Gung Memorial Hospital, 199, Tung Hwa North Road, Taipei, 105, Taiwan. Email: [email protected]
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
Authors: Manmeet S. Ahluwalia, Ahmad Ozair, Jan Drappatz, Xiaobu Ye, Sen Peng, Matthew Lee, Sanhita Rath, Harshil Dhruv, Yue Hao, Michael E. Berens, Tobias Walbert, Matthias Holdhoff, Glenn J. Lesser, Timothy F. Cloughesy, Andrew E. Sloan, Naoko Takebe, Marta Couce, David M. Peereboom, Burt Nabors, Patrick Y. Wen, Stuart A. Grossman, Lisa R. Rogers
Journal: Clinical Cancer Research (2024)

Patients with glioblastoma (GBM) have a dismal prognosis. Although the DNA alkylating agent temozolomide (TMZ) is the mainstay of chemotherapy, therapeutic resistance rapidly develops in patients. Base excision repair inhibitor TRC102 (methoxyamine) reverses TMZ resistance in preclinical glioma models. We aimed to investigate the efficacy and safety of oral TRC102+TMZ in recurrent GBM (rGBM).
Let’s Pump You Up!
Authors: Stephanie Y. Tsai, Jacqueline G. O’Leary
Journal: Hepatology (2024)

1Division of Liver and Digestive Disease, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA 2Veteran Affairs Hospital, Dallas, TX, USA Correspondence Jacqueline G. O'Leary, 4500 South Lancaster Rd., Dallas TX, 75216, Chief of Hepatology, Dallas VA Medical Center, Professor of Medicine, UTSW. Email: [email protected]
Physical exercise in liver diseases
Authors: Yunwei Zhang, Chunyan Cao, Chaofan Li, Russell G. Witt, Hai Huang, Allan Tsung, Hongji Zhang
Journal: Hepatology (2024)

Liver diseases contribute to ~2 million deaths each year and account for 4% of all deaths globally. Despite various treatment options, the management of liver diseases remains challenging. Physical exercise is a promising nonpharmacological approach to maintain and restore homeostasis and effectively prevent and mitigate liver diseases. In this review, we delve into the mechanisms of physical exercise in preventing and treating liver diseases, highlighting its effects on improving insulin sensitivity, regulating lipid homeostasis, and modulating immune function. In addition, we evaluate the impact of physical exercise on various liver diseases, including liver ischemia/reperfusion injury, cardiogenic liver disease, metabolic dysfunction–associated steatotic liver disease, portal hypertension, cirrhosis, and liver cancer. In conclusion, the review underscores the effectiveness of physical exercise as a beneficial intervention in combating liver diseases.
Reply: Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Authors: Andres Duarte-Rojo, Bachir Taouli, Daniel H. Leung, Deborah Levine, Tarek Nayfeh, Bashar Hasan, Yahya Alsawaf, Samer Saadi, Abdul Mounaem Majzoub, Apostolos Manolopoulos, Samir Haffar, Ayca Dundar, M. Hassan Murad, Don C. Rockey, Mouaz Alsawas, Richard K. Sterling
Journal: Hepatology (2024)

Duarte-Rojo, Andres; Taouli, Bachir; Leung, Daniel H.; Levine, Deborah; Nayfeh, Tarek; Hasan, Bashar; Alsawaf, Yahya; Saadi, Samer; Majzoub, Abdul Mounaem; Manolopoulos, Apostolos; Haffar, Samir; Dundar, Ayca; Murad, M. Hassan; Rockey, Don C.; Alsawas, Mouaz; Sterling, Richard K. Author Information